.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
AstraZeneca
Baxter
Mallinckrodt
Deloitte
Fish and Richardson
Express Scripts
Johnson and Johnson
McKesson
Farmers Insurance

Generated: November 19, 2017

DrugPatentWatch Database Preview

DYANAVEL XR Drug Profile

« Back to Dashboard

Which patents cover Dyanavel Xr, and when can generic versions of Dyanavel Xr launch?

Dyanavel Xr is a drug marketed by Tris Pharma Inc and is included in one NDA. There are five patents protecting this drug.

This drug has twenty-one patent family members in fourteen countries.

The generic ingredient in DYANAVEL XR is amphetamine. There are fifty-three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the amphetamine profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Tris Pharma Inc
DYANAVEL XR
amphetamine
SUSPENSION, EXTENDED RELEASE;ORAL208147-001Oct 19, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Tris Pharma Inc
DYANAVEL XR
amphetamine
SUSPENSION, EXTENDED RELEASE;ORAL208147-001Oct 19, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Tris Pharma Inc
DYANAVEL XR
amphetamine
SUSPENSION, EXTENDED RELEASE;ORAL208147-001Oct 19, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Tris Pharma Inc
DYANAVEL XR
amphetamine
SUSPENSION, EXTENDED RELEASE;ORAL208147-001Oct 19, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Tris Pharma Inc
DYANAVEL XR
amphetamine
SUSPENSION, EXTENDED RELEASE;ORAL208147-001Oct 19, 2015RXYesYes► Subscribe► Subscribe► Subscribe
Tris Pharma Inc
DYANAVEL XR
amphetamine
SUSPENSION, EXTENDED RELEASE;ORAL208147-001Oct 19, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: DYANAVEL XR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,549,989Modified release formulations containing drug-ion exchange resin complexes► Subscribe
8,202,537Modified release formulations containing drug-ion exchange resin complexes► Subscribe
8,790,700Modified release formulations containing drug-ion exchange resin complexes► Subscribe
9,522,191Modified release formulations containing drug--ion exchange resin complexes► Subscribe
8,491,935Modified release formulations containing drug-ion exchange resin complexes► Subscribe
9,675,704Modified release formulations containing drug-ion exchange resin complexes► Subscribe
8,337,890Modified release formulations containing drug-ion exchange resin complexes► Subscribe
9,198,864Modified release formulations containing drug-ion exchange resin complexes► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: DYANAVEL XR

Country Document Number Estimated Expiration
Japan2009530298► Subscribe
Denmark2428205► Subscribe
BrazilPI0709606► Subscribe
Spain2396039► Subscribe
South Korea20080108520► Subscribe
Israel194042► Subscribe
Taiwan200812649► Subscribe
Australia2007227569► Subscribe
China102488652► Subscribe
World Intellectual Property Organization (WIPO)2007109104► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Argus Health
Federal Trade Commission
Johnson and Johnson
Queensland Health
Colorcon
Chubb
Accenture
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot